Reduction	reduction	O	O	O	O
of	of	O	O	O	O
pain	pain	O	DISEASE	OTHERS	I
during	during	O	O	O	O
induction	induction	O	O	O	O
with	with	O	O	O	O
target-controlled	target-controlled	O	O	O	O
propofol	propofol	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
remifentanil	remifentanil	O	O	OTHERS	I
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
Pain	pain	O	DISEASE	OTHERS	I
on	on	O	O	O	O
injection	injection	O	O	O	O
of	of	O	O	O	O
propofol	propofol	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
unpleasant	unpleasant	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
hypothesized	hypothesized	O	O	O	O
that	that	O	O	O	O
propofol	propofol	CHEMICALS	O	OTHERS	I
infusion	infusion	O	O	O	O
pain	pain	O	DISEASE	OTHERS	I
might	might	O	O	O	O
be	be	O	O	O	O
prevented	prevented	O	O	O	O
by	by	O	O	O	O
infusing	infusing	O	O	O	O
remifentanil	remifentanil	O	O	OTHERS	I
before	before	O	O	O	O
starting	starting	O	O	O	O
the	the	O	O	O	O
propofol	propofol	CHEMICALS	O	OTHERS	I
infusion	infusion	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
clinical	clinical	O	O	O	O
setting	setting	O	O	O	O
where	where	O	O	O	O
target-controlled	target-controlled	O	O	O	O
infusions	infusions	O	O	O	O
(	(	O	O	O	O
TCI	tci	O	O	O	O
)	)	O	O	O	O
of	of	O	O	O	O
both	both	O	O	O	O
drugs	drugs	O	O	O	O
were	were	O	O	O	O
used	used	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
prospective	prospective	O	O	O	O
,	,	O	O	O	O
randomized	randomized	O	O	O	O
,	,	O	O	O	O
double-blind	double-blind	O	O	O	O
,	,	O	O	O	O
placebo-controlled	placebo-controlled	O	O	O	O
trial	trial	O	O	O	O
was	was	O	O	O	O
performed	performed	O	O	O	O
to	to	O	O	O	O
determine	determine	O	O	O	O
the	the	O	O	O	O
effect-site	effect-site	O	O	O	O
concentration	concentration	O	O	O	O
(	(	O	O	O	O
Ce	ce	O	O	OTHERS	I
)	)	O	O	O	O
of	of	O	O	O	O
remifentanil	remifentanil	O	O	OTHERS	I
to	to	O	O	O	O
prevent	prevent	O	O	O	O
the	the	O	O	O	O
pain	pain	O	DISEASE	OTHERS	I
without	without	O	O	O	O
producing	producing	O	O	O	O
complications	complications	O	O	O	O
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
A	a	O	O	O	O
total	total	O	O	O	O
of	of	O	O	O	O
128	128	O	O	O	O
patients	patients	O	O	O	O
undergoing	undergoing	O	O	O	O
general	general	O	O	O	O
surgery	surgery	O	O	O	O
were	were	O	O	O	O
randomly	randomly	O	O	O	O
allocated	allocated	O	O	O	O
to	to	O	O	O	O
receive	receive	O	O	O	O
normal	normal	O	O	O	O
saline	saline	O	O	O	O
(	(	O	O	O	O
control	control	O	O	O	O
)	)	O	O	O	O
or	or	O	O	O	O
remifentanil	remifentanil	O	O	OTHERS	I
to	to	O	O	O	O
a	a	O	O	O	O
target	target	O	O	O	O
Ce	ce	O	O	OTHERS	I
of	of	O	O	O	O
2	2	O	O	O	O
ng	ng	O	O	OTHERS	I
ml(-1	ml(-1	O	O	O	O
)	)	O	O	O	O
(	(	O	O	O	O
R2	r2	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
4	4	O	O	O	O
ng	ng	O	O	OTHERS	I
ml(-1	ml(-1	O	O	O	O
)	)	O	O	O	O
(	(	O	O	O	O
R4	r4	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
or	or	O	O	O	O
6	6	O	O	O	O
ng	ng	O	O	OTHERS	I
ml(-1	ml(-1	O	O	O	O
)	)	O	O	O	O
(	(	O	O	O	O
R6	r6	O	O	O	O
)	)	O	O	O	O
administered	administered	O	O	O	O
via	via	O	O	O	O
TCI	tci	O	O	O	O
.	.	O	O	O	O

After	after	O	O	O	O
the	the	O	O	O	O
target	target	O	O	O	O
Ce	ce	O	O	OTHERS	I
was	was	O	O	O	O
achieved	achieved	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
infusion	infusion	O	O	O	O
of	of	O	O	O	O
propofol	propofol	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
started	started	O	O	O	O
.	.	O	O	O	O

Remifentanil-related	remifentanil-related	O	O	O	O
complications	complications	O	O	O	O
were	were	O	O	O	O
assessed	assessed	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
remifentanil	remifentanil	O	O	OTHERS	I
infusion	infusion	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
pain	pain	O	DISEASE	OTHERS	I
caused	caused	O	O	O	O
by	by	O	O	O	O
propofol	propofol	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
evaluated	evaluated	O	O	O	O
using	using	O	O	O	O
a	a	O	O	O	O
four-point	four-point	O	O	O	O
scale	scale	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
propofol	propofol	CHEMICALS	O	OTHERS	I
infusion	infusion	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
pain	pain	O	DISEASE	OTHERS	I
was	was	O	O	O	O
significantly	significantly	O	O	O	O
lower	lower	O	O	O	O
in	in	O	O	O	O
Groups	groups	O	O	O	O
R4	r4	O	O	O	O
and	and	O	O	O	O
R6	r6	O	O	O	O
than	than	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
control	control	O	O	O	O
and	and	O	O	O	O
R2	r2	O	O	O	O
groups	groups	O	O	O	O
(	(	O	O	O	O
12/32	12/32	O	O	O	O
and	and	O	O	O	O
6/31	6/31	O	O	O	O
vs	vs	O	O	O	O
26/31	26/31	O	O	O	O
and	and	O	O	O	O
25/32	25/32	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
,	,	O	O	O	O
P<0.001	p<0.001	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Pain	pain	O	DISEASE	OTHERS	I
was	was	O	O	O	O
less	less	O	O	O	O
severe	severe	O	O	O	O
in	in	O	O	O	O
Groups	groups	O	O	O	O
R4	r4	O	O	O	O
and	and	O	O	O	O
R6	r6	O	O	O	O
than	than	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
control	control	O	O	O	O
and	and	O	O	O	O
R2	r2	O	O	O	O
groups	groups	O	O	O	O
(	(	O	O	O	O
P<0.001	p<0.001	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
both	both	O	O	O	O
incidence	incidence	O	O	O	O
and	and	O	O	O	O
severity	severity	O	O	O	O
of	of	O	O	O	O
pain	pain	O	DISEASE	OTHERS	I
were	were	O	O	O	O
not	not	O	O	O	O
different	different	O	O	O	O
between	between	O	O	O	O
Groups	groups	O	O	O	O
R4	r4	O	O	O	O
and	and	O	O	O	O
R6	r6	O	O	O	O
.	.	O	O	O	O

No	no	O	O	O	O
significant	significant	O	O	O	O
complications	complications	O	O	O	O
were	were	O	O	O	O
observed	observed	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
During	during	O	O	O	O
induction	induction	O	O	O	O
of	of	O	O	O	O
anaesthesia	anaesthesia	O	O	O	O
with	with	O	O	O	O
TCI	tci	O	O	O	O
of	of	O	O	O	O
propofol	propofol	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
remifentanil	remifentanil	O	O	OTHERS	I
,	,	O	O	O	O
a	a	O	O	O	O
significant	significant	O	O	O	O
reduction	reduction	O	O	O	O
in	in	O	O	O	O
propofol	propofol	CHEMICALS	O	OTHERS	I
infusion	infusion	O	O	O	O
pain	pain	O	DISEASE	OTHERS	I
was	was	O	O	O	O
achieved	achieved	O	O	O	O
without	without	O	O	O	O
significant	significant	O	O	O	O
complications	complications	O	O	O	O
by	by	O	O	O	O
prior	prior	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
remifentanil	remifentanil	O	O	OTHERS	I
at	at	O	O	O	O
a	a	O	O	O	O
target	target	O	O	O	O
Ce	ce	O	O	OTHERS	I
of	of	O	O	O	O
4	4	O	O	O	O
ng	ng	O	O	OTHERS	I
ml(-1	ml(-1	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

